Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Raynaud's Phenomenon
Interventions
DRUG

oral treprostinil

Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase

DRUG

Placebo

Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

United Therapeutics

INDUSTRY

lead

Brigham and Women's Hospital

OTHER